Search results
Dr. Jason Kelly is the co-founder and CEO of Ginkgo Bioworks. Ginkgo is a synthetic biology company headquartered in Boston, MA that programs cells for customers in the chemical, pharmaceutical, food and energy industries. The company recently raised over $930M in venture capital to expand their automated genetic engineering foundries and is ...
Order from BAM. Order from IndieBound. Info. Buy now! Info. Buy now! Info. Buy now! Info.
13,864. 6.8%. Hello and welcome! I’m Jason Kelly. I wrote the bestselling Neatest Little Guide to Stock Market Investing and The 3% Signal, and spent years developing a rules-based approach to the stock market that reacts to quarterly price changes.
Feb 17, 2023 · Jason Kelly will chair the commission while heading Ginkgo, with a roughly 6% stake in the company currently valued at over $100 million. ... Kelly will have a chance to advocate more formally.
May 11, 2021 · Ginkgo Bioworks cofounders Tom Knight, Reshma Shetty, Jason Kelly, Barry Canton and Austin Che . Michael Prince for Forbes. Synthetic biology pioneer Ginkgo Bioworks agreed to go public today in a ...
Nov 8, 2019 · The hot new buzzword in tech is synthetic biology. Its main purveyor is a startup with hundreds of millions in investment and a valuation of $4.2 billion. Gingko Bioworks CEO Jason Kelly spoke ...
- 24 min
Jason Kelly Chief Executive Officer. Jason Kelly is the co-founder and CEO of Ginkgo Bioworks. He has served as a member of our board of directors since Ginkgo’s founding in 2008. He has also served as a director of CM Life Sciences II Inc. (Nasdaq: CMII), a special purpose acquisition company with a focus on the life sciences sector, since ...
